On May 22, 2025, Outlook Therapeutics, Inc. announced an underwriting agreement for the sale of 9,285,714 shares of common stock and accompanying warrants, expected to raise approximately $13.0 million in gross proceeds. Each share and warrant set is priced at $1.40, with the offering closing around May 27, 2025.